Investor Presentaiton

Top-tier talent Differentiated process Scalable platform Benefits of Royalty Pharma platform and scale will grow Number of transactions (by transaction type) >2x 28 Synthetics 12 Synthetics M&A related Third-party M&A related Third-party 2012-2016 2017-2021 ROYALTY PHARMA 1. Includes subsequent transactions where Royalty Pharma acquired multiple royalty interests on the same therapy. Royalties acquired (1) (by approval phase) >2x 35 Approved 15 Approved Development- stage Development- stage 2012-2016 2017-2021 68

View entire presentation